Until 2016, the broad consensus was that the results of all trials involving patients with tumours without MGMT promoter methylation showed no detriment from the omission of temozolomide99, challenging the view that this agent should be used in every patient regardless of MGMT promoter methylation status. The gene discussed is MGMT; the disease is neoplasm.